515PTepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor receptor (EGFR)-mutant non-small lung cancer (NSCLC): Phase II data.

Autor:	Wu, Y-L1 (AUTHOR), Zhou, J2 (AUTHOR), Lu, S3 (AUTHOR), Zhang, Y4 (AUTHOR), Zhao, J5 (AUTHOR), Pan, H6 (AUTHOR), Chen, Y-M7 (AUTHOR), Chian, C-F8 (AUTHOR), Bruns, R9 (AUTHOR), Johne, A9 (AUTHOR)
Zdroj:	Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. 1 Chart.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu